NEW YORK / May 08, 2024 / Business Wire / Oscar Health, Inc. (“Oscar” or the “Company”) (NYSE: OSCR), a leading healthcare technology company, today announced that Chief Financial Officer, Scott Blackley, is scheduled to present and provide a business update at the BofA Securities 2024 Global Health Care Conference on Wednesday, May 15, 2024 at approximately 8:40 AM PT (11:40 AM ET) in Las Vegas, NV.
All interested parties are invited to listen to a live webcast of the fireside chat by visiting www.ir.hioscar.com and selecting the “Events & Presentations” link. Following the presentation, a webcast replay will be available on Oscar’s investor relations website for a period of 90 days.
About Oscar Health
Oscar Health, Inc. (“Oscar”) is the first health insurance company built around a full stack technology platform and a relentless focus on serving its members. At Oscar, our mission is to make a healthier life accessible and affordable for all. Headquartered in New York City, Oscar has been challenging the healthcare system's status quo since our founding in 2012. The company’s member-first philosophy and innovative approach to care has earned us the trust of over 1.4 million members, as of March 31, 2024. We offer Individual & Family and Small Group plans, and +Oscar, our full stack technology platform, to others within the provider and payor space. Our vision is to refactor healthcare to make good care cost less. Refactor is a term used in software engineering that means to improve the design, structure, and implementation of the software, while preserving its functionality. At Oscar, we take this definition a step further. We improve our members’ experience by building trust through deep engagement, personalized guidance, and rapid iteration.
Last Trade: | US$15.91 |
Daily Change: | 0.63 4.12 |
Daily Volume: | 8,534,369 |
Market Cap: | US$3.370B |
February 04, 2025 November 07, 2024 August 22, 2024 August 07, 2024 |
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MORECue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MOREEnd of content
No more pages to load